The summary for the NIAID Advanced Technology SBIR (NIAID-at-SBIR [R43/R44]) Federal Grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the government agency that is offering this grant.
NIAID Advanced Technology SBIR (NIAID-at-SBIR [R43/R44]): Purpose. This funding opportunity announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the SBIR program. For this FOA, "advanced technology" is defined as a clearly identified product or service that requires approval of the Food and Drug Administration (FDA) and is in one of the following three research areas: A vaccine, biologic, or drug to treat an infectious disease, an immunologic disease, allergy, or transplantation; A vaccine, biologic or drug delivery system; Assays for the diagnosis of an infectious disease, immunologic disease, allergic disease, or as an aid to transplantation, or therapeutic monitoring systems for clinical trials of vaccines, biologics, drugs or transplantation. An example of a clearly identified product is a research project focused on a lead compound for an AIDS drug. A research project focused on developing an assay to identify lead compounds does not have a clearly identified product and would not be appropriate for this FOA. Only applications meeting the above advanced technology definition should be submitted in response to this FOA. Applications in response to this FOA should not contain human clinical trials.